Why Are Shares of Viatris (VTRS) Down Today?

This morning we watched Viatris drop -1.7% to a price of $11.8 per share. The large-cap Drug Manufacturing company is now trading -18.13% below its average target price of $14.42. Analysts have set target prices ranging from $9 to $35 per share for Viatris, and have given the stock an average rating of hold.

Viatris's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.3%. The stock's short ratio is 2.26. The company's insiders own 0.21% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 75.7%. In conclusion, we believe there is mixed market sentiment regarding Viatris.

Institutions Invested in Viatris

Holder Shares Date Reported Percentage Value
Vanguard Group, Inc. (The) 145,344,236 2022-06-29 12% $1,521,754,150
Blackrock Inc. 93,510,570 2022-06-29 8% $979,055,667
State Street Corporation 58,084,474 2022-06-29 5% $608,144,442
Davis Selected Advisers, LP 55,466,147 2022-06-29 5% $580,730,559
Wellington Management Group, LLP 55,233,099 2022-06-29 5% $578,290,546
Geode Capital Management, LLC 24,881,035 2022-06-29 2% $260,504,436
Camber Capital Management LP 23,000,000 2022-06-29 2% $240,810,000
Deerfield Management Company, L.P. (Series C) 20,673,700 2022-06-29 2% $216,453,639
Laurion Capital Management, LP 18,421,408 2022-06-29 2% $192,872,141
Schroder Investment Management Group 16,529,051 2022-06-29 1% $173,059,163
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.